NEU2 and cancer: Keiko Hata et al. found different levels of ganglioside activity in cancer patients, and evaluated the sialidase NEU2 subtype as a potential biomarker for human cancer diagnosis by enzyme-linked immunosorbent assay (ELISA) 54.